Trial Bolsters Three Drug Combination Treatment as Standard After First Multiple Myeloma Relapse

Published Jun 7, 2019

Trial Bolsters Three Drug Combination Treatment as Standard After First Multiple Myeloma Relapse

A new trial confirms the effectiveness of pomalidomide in treating lenalidomide resistant multiple myeloma

NOW
PLAYING
New Hope For Esophageal Cancer Patients -- Immunotherapy Opdivo Approved For Treatment Of Advanced Esophageal Cancer
NOW
PLAYING
Mainstay of Treatment for Myeloma, Dexamethasone, Shows Very Significant Survival Benefit for COVID-19 Patients
NOW
PLAYING
Which Triple-Drug Regimen is a Better Frontline Treatment for Multiple Myeloma?
NOW
PLAYING
Ovarian Cancer - New PARP Inhibitor Combination Drug Approval
NOW
PLAYING
You May Be Eligible For a PARP Inhibitor - How to Decide?
NOW
PLAYING
Ovarian Cancer: Who Benefits From PARP Inhibitors?
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.